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Despite major improvements over the past several decades, many patients undergoing hematopoietic stem
cell transplantations (HSCT) continue to suffer from signiﬁcant treatment-related morbidity and mortality.
Clinical research studies (trials) have been integral to advancing the standard of care in HSCT. However, 1 of
the biggest challenges with clinical trials is the low participation rate. Although barriers to participation in
cancer clinical trials have been previously explored, studies speciﬁc to HSCT are lacking. The current study
was undertaken to examine the knowledge, attitudes, and perceptions of HSCT patients regarding clinical
trials. As members of focus groups, participants responded to open-ended questions that assessed factors
inﬂuencing decision-making about HSCT clinical trials. Suggestions for improvements in the recruitment
process were also solicited among participants. Seventeen adult HSCT patients and 6 parents of pediatric
HSCT patients participated in the study. The median age was 56 years (range, 18 to 70) and 44 years (range, 28
to 54) for adult patients and parents, respectively. Participants universally indicated that too much infor-
mation was provided within the informed consents and they were intimidated by the medical and legal
language. Despite the large amount of information provided to them at the time of study enrollment, the
participants had limited knowledge retention and recall of study details. Nevertheless, participants reported
overall positive experiences with clinical trial participation and many would readily choose to participate
again. A common concern among participants was the uncertainty of study outcome and general lack of
feedback about results at the end of the study. Participants suggested that investigators provide more
condensed and easier to understand informed consents and follow-up of study ﬁndings. These ﬁndings could
be used to help guide the development of improved consent documents and enhanced participation in
research studies, thereby affecting the future design of HSCT research protocols.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a high-
risk medical procedure that is utilized worldwide as therapy
for many malignant and nonmalignant hematologic dis-
eases [1,2]. The number of autologous and allogeneic trans-
plantations performed continues to rise [3], particularly as
outcomes have signiﬁcantly improved over the past few
decades [4]. Clinical research has played an important role in
advances of standard of care seen in HSCT patients over timeedgments on page 1611.
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14.06.020[5,6], which has led to improved supportive care, better
understanding of disease risks, and newer treatment ap-
proaches [4]. Nonetheless, efﬁcacy is still limited by short-
and long-term treatment-related complications [1]. Clinical
research remains crucial in guiding more effective diagnostic
and treatment options [7].
Clinical research has been broadly deﬁned by the Institute
of Medicine to “include all studies intended to produce
knowledge valuable to understanding the prevention, diag-
nosis, prognosis, treatment, or cure of human disease” [8].
The translation of basic science advances into human appli-
cations provides the opportunity to test hypothesis-driven
questions, investigate new therapies, and evaluate out-
comes in efforts to improve overall health care [9]. However,
1 of the biggest challenges is that very few patients enterTransplantation.
Table 1
Moderator Guide Questions
Free associations with term “clinical trial”
When you hear the word, “clinical trial”what is the ﬁrst thing that comes
to your mind?
Perceptions of information ﬂow regarding HSCT clinical trials
Now I’d like you to think back to the time when you had the bone
marrow transplantation* at the University of Michigan, or your child had
the bone marrow transplantation. Who presented the trial to you, who
talked to you about the trial?
How many trials were you offered, or presented? What kind of trials
were you offered?
When the person talked to you about the trial, whether it was the doctor
or the clinical coordinator, what did they say about it?What information
did they give you?
Did anyone have the feeling that they were given too much information,
or not enough information?
After learning about the BMT trial, or the trials that you participated in,
did you actively look for more information about it?
Decision-making process for participation in an HSCT clinical trial
Do you remember your ﬁrst thoughts when you heard about the BMT
trial at the U of M Hospital?
When it came to making a decision whether to participate in the BMT
trial or not, did you make the decision alone, or did someone else
inﬂuence or talk with you before you made the decision?
Reasons for and against participation in clinical trials
What are reasons to participate in a clinical trial?
What are reasons not to participate in a clinical trial?
Personal experiences with clinical trials
Now thinking back to the BMT trial that you participated in at the U of M
hospital, what were your experiences with these BMT trials?
Looking back and comparing your expectations before the start of the
trial with what actually happened during the trial, to what extent were
your expectations met. Was there anything that happened that was
different than you were expecting?
Thinking back to the overall experience that you had with the clinical
trial, as part of your BMT at the U of M hospital, if you would have to
make the decision about participating in a clinical trial again, how
willing would you be to participate in the same trial again?
Now imagine that a good friend or close relative comes to you tomorrow
and tells you that he or she was offered to participate in a clinical trial as
part of a BMT. What would you say to him or her?
Suggestion for changes in the HSCT clinical trial process at the
University of Michigan Health System
Thinking back to the BMT trials at the UM hospital. Is there anything that
you would like to change?
* To facilitate patients’ and parents’ understanding in the focus groups,
the more colloquial terms “bone marrow transplantation” and “BMT” were
used instead of “hematopoietic stem cell transplantations” and “HSCT.”
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adults with cancer participate in clinical trials [7,10]. Barriers
to enrollment in patients undergoing HSCT are additionally
magniﬁed because of the small pool of patients undergoing
transplantations at most centers and the substantial het-
erogeneity of diseases treated, donor and recipient charac-
teristics, and sources of hematopoietic stem cells, as well as
heterogeneity of transplantation techniques [5]. The conse-
quences of poor recruitment or slower than anticipated
enrollment into clinical research studies include premature
closure, underpowered results, lack of generalizability, and
wasted resources [11]. Although studies have explored bar-
riers to participation in cancer clinical trials, identifying
common themes across studies has been challenging [12].
Further, studies speciﬁc to HSCT are lacking [5]. Gaps in
knowledge remain regarding patient-centered perspectives
in HSCT clinical trials. Moreover, relatively little has been
published on how to recruit patients for HSCT clinical trials.
Given the growing importance of patient engagement in
clinical and translational research [13,14], we sought to
identify knowledge, attitudes, and perceptions of participa-
tion in clinical research studies among adult HSCT patients
and parents of pediatric HSCT patients. The purpose of our
study was to examine patient-centered barriers, facilitators,
and motivations regarding clinical research studies to
develop a questionnaire targeted at the HSCT population. By
investigating patient-centered attitudes and perceptions, the
new information gained may improve the future design of
HSCT clinical research protocols and improve participation
into HSCT clinical trials.
METHODS
Empirical Setting
A distinguishing feature of the University of Michigan blood andmarrow
transplantation (BMT) program is the integration of the adult and pediatric
BMT units to promote clinical and translational research. The inpatient and
outpatient units for the adult and pediatric BMT programs are located in the
Children’s and Women’s Hospital. The adult and pediatric BMT programs
have over 6000 annual outpatient visits, evaluate over 400 new HSCT pa-
tients, and perform approximately 250 HSCT each year (200 adult HSCT and
50 pediatric HSCT). This includes approximately 70 allogeneic HLA-identical
sibling donor and 70 unrelated donor HSCT. It is standard practice for HSCT-
eligible patients to consent to usual care procedures concurrently with as
many clinical research studies as possible, including sample repository,
ancillary, supportive care, and intervention studies, before admission to the
BMT unit.
Focus Group Recruitment
We sought participants who had recently undergone autologous or
allogeneic HSCT. Adult post-HSCT patients (age 18 years) and parents of
pediatric post-HSCT patients (age <18 years) were eligible to participate in
the focus groups. Patients were not required to have previously enrolled in a
speciﬁc clinical trial. Inclusion criteria required ability to speak and read
proﬁciently in English and ability to travel off-site to a facility on the Uni-
versity of Michigan main campus. Participants were recruited in the outpa-
tient setting through institutional review boardeapproved ﬂyers posted in
the BMT program waiting rooms or attached to patient clipboards during
clinic check-in. BMT physicians, advanced practice extenders, and staff
assisted with recruitment.
Interested patients/parents were instructed to call a telephone number
and sign-up for 1 of 3 focus groups (FG1, FG2, and FG3). After answering a
short screening questionnaire over the phone, participants received an in-
formation package, including a cover letter conﬁrming their participation, a
map with driving directions to the focus group location, and a consent form
via mail or e-mail. Participants received a telephone call reminder on the
day before the scheduled focus group.
Participants of FG1 and FG2 received $50 as compensation for partici-
pation. To encourage participation among parents for FG3, compensation
was increased to $100. Participants were reimbursed for metered parking
during the time of the focus group. The studywas approved by the University
of Michigan Medical School’s institutional review board (HUM00078723:
“Attitudes and perceptions of participation in BMT clinical trials”).Focus Groups
Three focus groups were conducted between September and October
2013. Upon arrival to the focus group site, participants signed the consent
form and ﬁlled out a brief questionnaire that collected information on socio-
demographic and clinical characteristics. No patient identiﬁers were
retained. Each focus group lasted approximately 90 minutes and was audio/
video-recorded with consent provided by the participants.
A trained focus groupmoderator with a background in public health and
an assistant moderator with a background in survey methodology, neither
afﬁliated with the BMT program, moderated all 3 focus groups. Researchers
from the BMT program attended the sessions and observed the discussions
behind a 1-way mirror. Before initiating the study, a focus group guide was
developed by the study investigators, who included experts in HSCT and
survey methodology, through a literature review on studies about motives
for cancer clinical research participation and through the conduct of semi-
structured qualitative interviews with BMT physicians, advanced practice
extenders (eg, nurse practitioners and physician assistants), nurse co-
ordinators, social workers, nutritionists, pharmacists, and nurses. The
moderators used the guide to cover questions on the following: (1) free
associations with the term “clinical trial,” which was used interchangeably
with “clinical research studies,” (2) perceptions of information ﬂow (ie,
process of recruitment) regarding HSCT trials, (3) the decision-making
process for participation in an HSCT clinical trial, (4) general reasons for
and against participation in clinical trials, (5) personal experiences with
clinical trials, and (6) suggestions for changes in the HSCT clinical trial
process at the University of Michigan Health System (Table 1 provides
F. Keusch et al. / Biol Blood Marrow Transplant 20 (2014) 1604e16111606details of the moderator guide questions). The last topic was added to the
guide for FG2 and FG3 based on comments from participants in FG1.Data Analysis
Focus group recordings were professionally transcribed verbatim. The
transcripts were systematically analyzed in multiple steps, using content
analysis by hand and computer-assisted qualitative data analysis to uncover
common themes pertaining to patient and parent attitudes and perceptions
of HSCT clinical research studies. The analysis approach included 3 steps,
as previously described [15]. First, 3 researchers (F.K., L.C., and S.W.C.)
independently read the transcripts and generated codes for the range of
responses. Codes were then reﬁned and verbally deﬁned, and a code frame
was developed using an iterative process based on discussions among the
entire group. Second, the 3 raters coded all transcripts independently,
compared codes, and resolved disagreements by consensus. Third, 1 mem-
ber of the research team (F.K.) used ATLAS.ti V7 (Berlin, Germany; http://
www.atlasti.com/index.html) to apply the codes to the transcript and to
create frequency tables of themes used by focus group participants. The
entire study team reviewed the results and validated the interpretations and
conclusions in a ﬁnal peer-debrieﬁng session (Figure 1 for the iterative loop
of qualitative data collection).Reporting
Reporting
Deliverable
Figure 1. Iterative loop of reRESULTS
Study Characteristics
Twenty-ﬁve subjects expressed interest in joining a focus
group, which included 19 adult HSCT patients and 6 parents
of pediatric HSCT patients. However, 2 were ultimately un-
able to join a focus group because of conﬂicting BMT clinic
appointments, leaving 23 individuals enrolled. Participants
included 17 adult HSCT patients and 6 parents of pediatric
HSCT patients (eg, 1 mother or father for each pediatric
patient) with a total of 4 mothers and 2 fathers. FG1 included
7 adult patients and 2 parents of pediatric patients, FG2
included 8 adult patients only, and FG3 included 4 parents of
pediatric patients and 2 young adult patients (age>18 years)
who were both treated in the pediatric BMT Unit.
For adult HSCT participants, median age was 56 years
(range, 18 to 70), and most were male (n ¼ 13); for parent
participants, the median age was 44 years (range, 28 to 54),
and most were female (n¼ 4) (Table 2). The majority of adultSolicit written response 
from Physicians 
regarding the role of 
BMT clinical trials
Interviews with BMT 
Physicians, Advanced 
Practice Extenders, 
Nurse Coordinators, 
Social Workers, 
Nutritionists, 
Pharmacists, and 
Nurses
Iteratively Develop 
Focus Group 
Questions over Several 
Meetings
Focus Group 1
Add Question 
Requesting 
Suggestions for 
Changing/Improving 
Clinical Trials
Focus Group 3
Analysis of Focus 
Group Data
Pre-transplant 
Interviews
Adapt Questions for 
Interviewing Pre-
transplant Patient 
Sample
Reflection/ 
Reorganization Data Collection
Questionnaire
Development
Survey Administration
Survey Data Analysis
Focus Group 2
Literature Review on 
Motives for 
Participation in Cancer 
Clinical Studies 
search methodology.
Table 2
Socio-demographic and Clinical Characteristics of the Sample
Adult
Patients
Parents of
Pediatric
Patients
No. of participants 17 6
Age, median (range), yrs 56 (18-70) 43.5 (28-54)
Gender
Male 13 (76.5) 2 (33.3)
Female 4 (23.5) 4 (66.7)
Hometown
Ann Arbor and other Washtenaw county 5 (29.4) 1 (16.7)
Other southeast Michigan 10 (58.5) 5 (83.3)
Other 2 (11.8) 0 (0)
Household income
Under $50,000 7 (41.2) 2 (33.3)
$50,000-$99,999 4 (23.5) 1 (16.7)
$100,00þ 5 (29.4) 3 (50)
N/A 1 (5.9) 0 (0)
Employment status
Full-time 1 (5.9) 1 (16.7)
Part-time 4 (23.5) 3
Not employed 12 (70.6) 2 (33.3)
Health care coverage
Private 5 (29.4) 2 (33.3)
Employer sponsored 7 (41.2) 2 (33.3)
Medicaid/Medicare 4 (23.5) 2 (33.3)
Other 1 (5.9) 0 (0)
Time since HSCT median (range), mo 18 (2-53) 19 (4-44)
Data are presented as n (%), unless otherwise indicated.
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pants (adult HSCT patients and parents) came from southeast
Michigan, the primary catchment area served by the Uni-
versity of Michigan Health System. The median time from
HSCT to the focus group was 18 and 19 months for adult
patients and parents, respectively. Additional characteristics
of the study population (adult HSCT patients and pediatric
patients represented by their parents) are provided in
Supplementary Table S1.Free Associations: “Clinical Trial”
Participants were asked to think about the term “clinical
trial” and state whatever came to mind (see Table 3 for
representative answers to the focus group questions). Most
associations coming from adult HSCT patients concerned the
uncertainty of the outcome of clinical trials (Supplementary
Table S2). In general, positive comments about research,
altruism, and personal beneﬁts gained through trial partici-
pation were mentioned frequently by adult patients. On the
contrary, parents of pediatric patients most often made
neutral comments about research, followed by associations
concerning desperation. Additionally, both adult patients
and parents mentioned the uncertainty associated with
clinical trial outcomes and general concerns with participa-
tion in trials, providing comments such as “guinea pig,” “lab
rat,” and “we are 1 step above the mice.”Perceptions of Information Flow Regarding HSCT Trials
at University of Michigan Health System
Participants were then asked to think back to the time
when they or their children were admitted for the HSCT
procedure and report whether theywere asked to participate
in any clinical research studies and, if so, who asked them to
participate. Although almost all participants remembered
being asked to participate in multiple studies by either their
primary BMT physician or a BMT nurse coordinator, bothadult patients and parents of pediatric patients expressed
recall difﬁculty when asked about what speciﬁc studies were
offered and what information was presented. In general,
studies involving patients providing extra blood and urine
samples were remembered most often. For other types of
studies, most participants could cite broad categories, such
as “graft-versus-host diseaseerelated” trials or studies in-
volving “genetics,” without recalling speciﬁc details. A few
participants were not sure whether they participated in any
studies (even though they had) or had problems drawing a
clear distinction between the clinical research studies and
the HSCT procedure itself.
When asked what the person who presented the trial told
them about the study, participants remembered mainly gen-
eral information on research, conﬁdentiality, and anonymity
or information about the low-risk or tangential nature of the
study (ie, blood draws for correlative laboratory studies). No
participants reported having received ﬁnancial compensation
for their participation in clinical research studies.
Many participants expressed that they were inundated
with too much information and intimidated by details on
side effects and the medical and legal language used in the
consent process. Other participants expressed that they
appreciated all the information they received to ensure that
they were well informed. Some participants reported having
actively searched formore information; however, most of the
search activities pertained to the HSCT itself and not the trial.Decision-making Process
Almost all participants reported that making the decision
about participating in the clinical research study was easy
and fast, mainly because they had the feeling that the studies
were low risk, in general, and did not require additional
effort apart from the usual care of the HSCT procedure itself.
Amajority of patients considered participation as “little or no
extra burden.” Additionally, altruism appeared to play a
major role for many participants in making a fast decision.
Adult patients made the participation decision with their
spouses or alone because they did not want to be inﬂuenced
by others. Parents of pediatric HSCT patients reported mak-
ing the decision about participation together with their
spouses and some also involved their children.Reasons for and Against Participation in Clinical Trial
Focus group participants were asked to list, on an index
card, up to 3 reasons for and 3 reasons against participation in
a clinical study and then share their reasons with the group.
The main reasons for participation cited by adult patients
were altruism and personal beneﬁts gained through partici-
pation (Supplementary Table S3). Other reasons reported by
adult patients involved the advancement of research, the
search for answers about their disease, and institutional pride
toward the University of Michigan. Parents of pediatric
patients most often reported advancement of research and
altruism.
In terms of reasons for not participating in clinical research
studies, both adult patients and parents of pediatric patients
reported fear of personal harm most often (Supplementary
Table S4). Additionally, many adult patients mentioned un-
certainty about the trial outcome and extra burden, such as
more visits to the hospital, as reasons for nonparticipation.
Parents also mentioned that distrust in a program or its doc-
tors would hold them from participating in a clinical research
study.
Table 3
Representative Participant Responses to Focus Group Questions
Free associations with term “clinical trial”
“It’s a trial because it’s a trial. It might not help me.” (AP)
“New medicine, new techniques.” (AP)
“Doing something that might help people further down the line.” (AP)
“I would just say medicine.” (P)
“Life-saving.” (P)
“Raises a red ﬂag to me.” (P)
Perceptions of information ﬂow regarding HSCT clinical trials
“The coordinator nurse. I can remember her face but not her name. She was the coordinator before I had my transplant. Then he [doctor] talked about it.” (AP)
“I have to be honest, I have no idea if I was in a trial or not. I was so sick. If I was signing stuff, I couldn’t tell you. I had no idea.” (AP)
“They talked about that it was going to help research on down to different drugs that they were going to try and that I could help people in the future, and it was
going to be no extra doctor visits.It didn’t affect me.Just extra vials of blood.And you had to pee.” (AP)
“I had blood, urine, bone marrow. And then the aspiration of part of it. And I did some trials for some therapies for graft-versus-host disease medicine. And I’m not
sure at 1 point there was some other medicine that I tried too. My memory’s blurry so I’m all.” (AP)
“I know we did the research blood. I don’t remember how many.” (P)
“I also think that at the time when they’re presenting the stuff and you’re signing the papers saying “Oh research! Yes, absolutely. You can do this.” But there was
so much more going on per se in our life at that time.” (P)
“I don’t think my son was in a trial because my daughter was a 100% match. So I don’t think that we did a trial. I think it was just a regular bone marrow
transplant.” (P)
“They said that it would be used only for that reason and everything remains conﬁdential—They won’t be using it for any other purpose than what the trial said in
the paperwork.And it was voluntary. You didn’t have to participate.” (P)
“Too much. Papers after papers.Just sum it up.” (AP)
“It’s a 10-page packet and every page is practically the same and you get to the side effects? I’m sorry. I’m sure that this has to do more with liability than
anything. .Literally every possible thing that you could consider as a liability is listed there..So, you don’t really know.What could possibly be a side effect
because everything, whether it’s a drug or whether it’s a clinical trial, they all put every possible side effect down and it’s like forget it.” (AP)
“By being informed it also gives you something to occupy your mind when you—So much is going through your head.” (AP)
Decision making process for participation in an HSCT clinical trial
“There’s basically no question about it. Yes, it’s something that they could do without even affecting your life or the outcome of the thing.” (AP)
“I was actually eager to help.because I just wanted to give back somehow.” (AP)
“I just didn’t want too many other people inﬂuencing my decision.At the end of the day, I just want to make sure that I was happy with the decision that I was
going to make.” (AP)
“My son is 8 but my wife and I have involved him in the decision-making process through every aspect of this journey. So he was involved in everything. His
signature is on all of the stuff. Even though it was not legally binding but he signed all his paperwork, too.” (P)
Reasons for participation in clinical trials
“My ﬁrst 1 is just because of my survival, and number 2 is to help further others in their treatment. Then, my biggest 1 is “science versus myth.”” (AP)
“I wrote to contribute to the science and beneﬁt others with improved protocols, to possibly beneﬁt my own recovery, and to potentially save my own life, worst
case scenario.” (AP)
“I’m very tied to this university. This is my school, this is my life, this is who I am so I really wanted to help the University of Michigan and I wanted to help them
innovate more above other schools, which I think is very important to being a Wolverine.” (AP)
“Access to curative medicine not otherwise available. More eyes on labs. And more labs per blood draw. Ability to help others.” (P)
“To save my son, to cure his leukemia. Good information on the bone marrow transplant and successful stories.” (P)
Reasons against participation in clinical trials
“I’d be less likely to if it required extra clinic visits, and if it sounded dangerous, and if it was something that may make my condition worse.” (AP)
“I have the fear of failure, the loss of life, and possible waste of time, and negative repercussions.” (AP)
“If there was a level of distrust. If you have a level of distrust with the program or the doctor that you’re with, you’re less likely to. This is another thing, they may
throw things at you. “Just sign this, we’re going to do this, bla-bla-bla,” reasons in the paperwork not clear enough, not explained fully. I would really go, “Hmm,
who are they doing this for? Me or them?”” (P)
“Risk, faster demise, more pain. More time away from family potentially. More doctors in the room during inpatient time.” (P)
Personal experiences with clinical trials
“I don’t really have anything particularlymemorable. It’s just stuff.I don’t know.Because I don’t remember.Maybe therewere some extra tests, I’mnot sure.” (AP)
“I didn’t affect us at all. We saw nothing except for a few extra vials of blood taken every so often.” (P)
“And cupfuls and cupfuls of pills, plus IVs. The clinical trial pills got tedious. After a while I was going, “Oh, not another 1.” On an empty stomach, that kind of
thing.” (AP)
“Okay, I did this, but now what? Did it help? Was it worth it? What did it prove?” (AP)
Suggestion for changes in the HSCT clinical trial process at the University of Michigan Health System
“I don’t even know if mine is over yet, the study I was in, if they’re still doing it, but I would love to get, as a member of the study, when the study results are done,
get notiﬁcation of the outcome of the study.What’s going on? I volunteered and then they shut you out.” (AP)
“We’re a litigious society. I understand that you need me to sign this contract or.A summary. Yes, summarize it..Give me the honest scoop of it. If you list 100
different side effects because they’re all possibilities and you’ve got to cover yourself for legalism, that’s ﬁne, but be.I need somebody to tell me which of these
things am I really likely to get or what’s most probable?” (AP)
“But there was so much going on per se in our life at that time. I don’t speciﬁcally remember them saying. ‘This is what this is and here’s a piece of paper telling
you.’ .I think that would have been helpful.” (P)
“I felt like there were some times where I felt like it was when I would be with my older siblings and they would be like, “Yes, eat the worm, it’s totally ﬁne,” and try
to convince me to do something that they would get amusement out of.” (AP)
AP indicates adult patient; P, parent of pediatric patient.
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When asked about their personal experience with par-
ticipating in a HSCT research study, participants, overall,
were positive. Many participants stated that the studies were
low risk and did not have much of an impact on them. Again,
some participants expressed recall difﬁculties about speciﬁcs
of the study. Only a few participants remembered side effectsand extra pain stemming from the studies. A common con-
cern among several participants, both adult patients and
parents of pediatric patients, pertained to the uncertainty
about the outcome of the study and the lack of feedback
patients received after they enrolled and completed the
study. Almost all participants said that they would partici-
pate again in a clinical research study. In addition, when
F. Keusch et al. / Biol Blood Marrow Transplant 20 (2014) 1604e1611 1609asked whether they would recommend that others, such as
friends and family in the same situation, participate in a
clinical study, there was strong support for doing so. How-
ever, many participants stressed the importance of being
informed about the details of the study and being provided
with ample opportunity to ask questions.
Suggestions for Changes in HSCT Clinical Trial Process
Focus group participants were asked whether there were
anything that they would like to change in the process of
HSCT clinical research studies at the University of Michigan
Health System. Again, many participants criticized the gen-
eral lack of feedback after a study had started. Additionally,
many participants repeated their concerns about the amount
of paperwork and the scientiﬁc and legal language involved
in the consent process. Some participants suggested that
investigators provide more condensed and personalized in-
formation and that the information be presented in a digital
format, such as in an electronic application or a tab on the
patient online portal. Finally, some adult patients felt some-
what pressured by their physicians to participate in certain
clinical research studies.
DISCUSSION
In this study, the majority of participants recognized the
important role of clinical trials in improving the standards of
HSCT medical care and they described their decision to
participate as valuable. Participants overall reported positive
attitudes towards HSCT clinical research. Here we describe 4
major themes identiﬁed and potential lessons learned that
could be used to improve the experiences of future HSCT
participants.
1. Information Overload Leading to Limited Recall
Many participants reported receiving too much informa-
tion about studies for which they were participating, result-
ing in them not being able to recall many details. We found
that participants were unable to articulate the type of trials
that they (or their child) participated in and had difﬁculty
distinguishing the clinical research participation components
from the HSCT procedure itself. Although ability to recall
study details is expected to decay over time [16], our ﬁndings
suggest that study participants did not fully comprehend the
implications of what they consented to, which is in accor-
dancewith priorwork [17,18]. Additional challenges persist in
HSCT because of complicated treatment plans or protocols
that are not easy to explain in layman’s language [19].
Nonetheless, a majority of participants expressed a desire
to be informed about the research studies inwhich theywere
participating and some actively searched for additional in-
formation. This highlights the difﬁcult task of ﬁnding the
right balance between providing too much and too little in-
formation to study participants, and about the potential need
to tailor discussions and the informed consent process
overall to the needs of each participant [20-22]. A recent
study demonstrated the feasibility of incorporating tailored
information into the consent process about potential
involvement for the National Cancer Institute/Department of
Veteran Affairs cosponsored Selenium and Vitamin E (Pros-
tate) Cancer Prevention Trial [17]. Both improved under-
standing and satisfaction were achieved with a modiﬁed
consent document that included a brief video.
Study participants described the beneﬁt of having a copy
of their consent forms, not as a legal record, but rather as a
resource to reference as newquestions arose or as a reminderof the details of the study. The participants felt that the
documents contained too much scientiﬁc and legal jargon,
suggesting that improving readability of these documents is
important beyond the initial consenting process [23]. The
National Institutes of Health and the National Heart Blood
and Lung Institute have produced templates to facilitate the
use of easy-to-read informed consent forms in cancer clinical
trials [24]. The Blood and Marrow Transplant Clinical Trials
Network is developing educational interventions to facilitate
the use of these easy-to-read informed consent forms and is
currently conducting a randomized, controlled trial of eval-
uating the effectiveness of the 2-column format [18].
2. Altruism as a Reason for Participation
Despite the information overload and a lack of under-
standing about clinical research, adult patients and parents of
pediatric HSCT patients were still drawn to participate in
research. Often, there are few options other than trial par-
ticipation forHSCT patients [25]. Theﬁnding that participants
reported altruistic motives as a primary driver for their
participation, including a desire to help the institution (ie,
institutional pride), is important because this provides in-
sight into the decision-making process of HSCT patients.
Despite the distress and uncertainty of illness, HSCT partici-
pants viewed clinical research as important and as an op-
portunity to improve scientiﬁc knowledge. Although both
adult patients and parents of pediatric patients expressed a
hope that the research would provide direct beneﬁt, parents
of children expressed greater desperation for any trial that
could improve the chances of a positive outcome, consistent
with prior work [26]. Our ﬁndings suggest that it may be
important to emphasize different but equally important as-
pects of clinical trials to improve participation rates (eg,
altruism or helping future adults and personal beneﬁts for
children). There are potential challenges to such an approach,
however, and keeping the ethical implications in mind re-
mains paramount [25].
3. Trust in the BMT Care Team
Our study suggests that patients and their families are
strongly inﬂuenced by the BMT care team’s recommenda-
tions and the trust placed in them,which has beenpreviously
observed in other cancer patients considering phase 3 ran-
domized controlled trial entry [27]. When asked who pre-
sented and reviewed information regarding the potential
clinical research studies, including informed consent forms,
patients and parents indicated either the BMT nurse coordi-
nator, BMT physician, or both. Although patients and parents
of children often discussed treatment and research partici-
pation options with their spouses and/or children, many of
the participants reported that they ultimately looked to their
BMT care team (eg, physicians and nurse coordinators) to
provide expert guidance about their decision to participate in
a trial and which trial(s) to join. Both adult patients and
parents valued the time spent with their BMT care team
explaining the research studies and ultimately looked to
them for guidance when weighing risks and beneﬁts. These
results are supported by other recently reported studies that
showed the importance of physician’s recommendations as
important determinants in participation [28,29].
Furthermore, our observations should prompt future
study on how best to inform patients about HSCT clinical
trials. Undoubtedly, the role of the BMT care team remains
critical as enhanced strategies are developed to improve the
recruitment process.
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It is common for clinical research protocols in HSCT to be
conducted in conjunction with routine clinical HSCT care
[25]. A majority of participants from all 3 focus groups used
the terms “BMT procedure” and “clinical research” inter-
changeably, and participants reported an inability to distin-
guish between research and routine care activities. For
example, participants often signed multiple consent forms
including those for transfusions and bone marrow biopsies,
as well as informed consent forms for standard HSCTmedical
care and clinical research trials. This not only overwhelmed
patients, but it also often confused them, as the clinical
research trial forms required that aspects of routine HSCT
care also be discussed. Thus, patients saw the same infor-
mation duplicated on multiple forms, making unclear which
aspects were routine and which were experimental.
In our study, patients suggested a summary document
listing distinctions between research and usual care, and
ordering the potential complications by frequency. As in-
vestigators design protocols and forms, only risks associated
with research-speciﬁc procedures should be identiﬁed. Risks
related to usual care procedures should be separate from
informed consent forms. However, regulatory agencies often
mandate certainmedical and legal language to be included by
investigators. Enhancing accrual to HSCT clinical trials is,
therefore, complex and requires amultidisciplinary approach
that can support more than just providing packets of
informed consent documents. We hope to better understand
infrastructure barriers in our future survey questionnaire.
It is, therefore, not surprising that the ideals of truly
informed consent are difﬁcult to achieve in practice [30].
Nevertheless, educational interventions and efforts to improve
the process, targeting the HSCT population speciﬁcally, are
underway [18]. Although the boundaries between research
and clinical care are not entirely clear [31], extended discus-
sions between investigators and research participants have
been shown to improve understanding [32], and incorporating
novel strategies, such as follow-up telephone calls, in-person
conversations, or use of health information technology tools,
are likely required.
Strengths and Limitations
Our study examined the perspectives of both adult BMT
patients and parents of pediatric BMT patients in the context
of a high-risk procedure. We investigated their attitudes,
motivations, and barriers toward participation in clinical
research studies by conducting 3 unique focus group ses-
sions. The sizes of the focus groups were evenly distributed
and were small enough to allow for adequate deliberation of
open-ended questions. The moderator’s guide was devel-
oped from input provided by BMT staff and ﬁndings from
previous research. These relevant topics, combined with the
moderator’s nonafﬁliation with the BMT program, likely
facilitated the open communication and interaction among
the group members.
We recognize a number of limitations, also, that need to
be addressed. First, the focus groups were conducted at a
single institution (University of Michigan) and the number of
participants was relatively small, particularly the parent
group, which may limit the generalizability of our ﬁndings.
Furthermore, there was a predominance of Caucasians and
the socio-demographic factors were also relatively homog-
enous. The study population was skewed toward allogeneic
HSCT patients (23 of the 25 participants). This was notsurprising, given that recruitment to the focus groups was
conducted in the outpatient setting. In general, allogeneic
patients at the University of Michigan are seen more
commonly in outpatient BMT clinics for routine post-HSCT
follow-up, whereas autologous patients are referred back to
their primary oncologists. As such, participants in the focus
groups were representative of those usually cared for and
managed by BMT physicians at the University of Michigan.
Second, it is possible that our results were inﬂuenced by
selection bias. As post-HSCT patients were recruited as out-
patients, only those who survived and whose physical health
was stable were included in the study. It is possible that their
relative healthy condition may have inﬂuenced their positive
attitude toward clinical research.
Third, it is possible that our qualitative research process
inﬂuenced the tendency for social desirability among par-
ticipants favoring their responses in a manner they wanted
to be perceived (eg, discussing altruistic reasons for partici-
pation rather than personal beneﬁts). In line with this, our
results may have been inﬂuenced by the effects of volunteer
participants. For example, the overall positive attitudes and
perceptions about clinical research may have been driven by
patients who take a more proactive approach in their health
care.
Lastly, we have no knowledge about those who declined
participation. For example, only 1 patient was documented in
the electronic medical record as declining an interventional
trial, but we did not explore additional information. We felt
this was unnecessary, as the objective of our study was to
develop a questionnaire and we anticipate that we will iden-
tify these patients later. It is likely that patients who partici-
pated in the focus group discussion were more inclined to
participate in research studies, in general [33]. Our ﬁndings
present a positive picture about clinical research studies
perceived by our HSCT population. Although our study pop-
ulation was composed primarily of post-HSCT patients
recruited to focus groups, we also sampled pre-HSCT patients
by conducting individual semi-structured qualitative in-
terviews (5 adults and 2 parents betweenNovember 2013 and
March 2014; data not shown). Because of challenges with
coordinating varying HSCT admission schedules, this was felt
to be an ideal researchmethodology for this cohortof patients.
In data not shown, the results from these pretransplantation
interviews conﬁrmed the ﬁndings of our focus groups. Pre-
transplantation respondents reported decision-making stra-
tegies, concerns, and hopes that were comparable to those of
the post-transplantation focus group participants. Interest-
ingly, pretransplantation respondents also indicated recall
difﬁculties about the details of the research studies only hours
after they were presented to them.
Based on the new knowledge generated in this study, we
are developing a survey to be administered to all new,
incoming HSCT patients. The design will include pre- and
post-HSCT administration. This will allow us to capture those
who declined participation and their reasons. It remains
important to elucidate how patients and parents are engaged
in the clinical research process. Moreover, surveying patients
before and after HSCT will also allow us to capture the more
clinically ill and high-risk inpatient cohort and follow their
trajectory longitudinally. The new information will be inte-
gral in improving the informational needs of HSCT patients
and possibly improving the process inwhich clinical research
studies are presented, reviewed, and discussed with the
patients and parents.
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The study herein was a unique approach to measuring
attitudes and opinions of HSCT patients and parents par-
ticipating in clinical research studies. The themes that em-
erged were not necessarily unique to HSCT patients, but they
present possible targets to improve the clinical research
process in a complex disease population. Patients valued
their ability to participate, as it provided a sense of purpose.
Altruism or personal beneﬁt were perceived as important
predictors of participation in clinical research studies. The
focus group approach allowed us to acquire feedback directly
from patients and parents. This research methodology
showed the importance of maintaining contact with partic-
ipants throughout the research and clinical care processes.
Providing follow-up after participation in clinical research
studies is highly desired by patients and parents, even simply
indicating, “Thank you for participating.”
Based on the new knowledge generated in this study, we
are developing a survey questionnaire to be administered to
all new, incoming HSCT patients. The designwill include pre-
and post-HSCT administration. This will allow us to capture
those who declined participation and their reasons. It re-
mains important to elucidate how patients and parents are
engaged in the clinical research process. Moreover, surveying
patients before and after HSCT will also allow us to capture
the more clinically ill and high-risk inpatient cohort and
follow their trajectory longitudinally. The new information
will be integral in improving the informational needs of
HSCT patients and possibly improving the process in which
clinical research studies are presented, reviewed, and dis-
cussed with patients and parents.
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